Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19
Status:
Recruiting
Trial end date:
2022-04-14
Target enrollment:
Participant gender:
Summary
The OVID study will show whether prophylactic-dose enoxaparin improves survival and reduces
unplanned hospitalizations in ambulatory patients aged 50 or older diagnosed with COVID-19, a
novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and
coagulation activation.
Phase:
Phase 3
Details
Lead Sponsor:
University of Zurich
Collaborators:
Centre Hospitalier Universitaire Vaudois Clinica Luganese Moncucco Mainz University Oncology Institute of Southern Switzerland University Hospital Freiburg University Hospital Inselspital, Berne University Hospital, Basel, Switzerland University Hospital, Geneva